<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74080">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141282</url>
  </required_header>
  <id_info>
    <org_study_id>M14-032</org_study_id>
    <nct_id>NCT02141282</nct_id>
  </id_info>
  <brief_title>A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy</brief_title>
  <official_title>A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech/Roche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy
      and safety of ABT-199 in approximately 120 subjects with relapsed or refractory CLL after
      B-cell receptor signaling pathway inhibitors (BCR PI) treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>To evaluate the efficacy of ABT-199 monotherapy in subjects with chronic lymphocytic leukemia (CLL) relapsed or refractory to B-cell Receptor Signaling Pathway Inhibitors. Assessed by the investigator, based on laboratory results, physical examinations, CT scans, and bone marrow examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The number of days from the date of first response (complete response (CR) or partial response (PR)) to the earliest recurrence or disease progression (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Measured up to 5 years after the last subject has enrolled in the study.</time_frame>
    <description>The number of days from the date of first dose or enrollment if not dosed to the date of earliest PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Measured up to 5 years after the last subject has enrolled in the study.</time_frame>
    <description>The number of days from the date of first dose to the date of earliest PD or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Measured up to 5 years after the last subject has enrolled in the study.</time_frame>
    <description>The number of days from the date of first dose to the date of death for all dosed subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Time to Next Anti-CLL Treatment (TNT)</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The number of days from the date of first dose of ABT-199 to the date of first dose of new non-protocol anti-leukemia therapy (NPT) or death from any cause</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of minimal residual disease (MRD) negativity status</measure>
    <time_frame>Measured up to 2 years after the last subject has enrolled in the study.</time_frame>
    <description>The presence of less that once CLL cell per 10,000 leukocytes in either peripheral blood and/or bone marrow</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>ABT-199 after ibrutinib therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily doses increasing weekly as tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199 after idelalisib therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily doses increasing weekly as tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT-199 after ibrutinib or idelalisib therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single daily doses increasing weekly as tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-199</intervention_name>
    <description>ABT-199 monotherapy</description>
    <arm_group_label>ABT-199 after ibrutinib therapy</arm_group_label>
    <arm_group_label>ABT-199 after idelalisib therapy</arm_group_label>
    <arm_group_label>ABT-199 after ibrutinib or idelalisib therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a diagnosis of CLL that meets 2008 Modified International Workshop
             on Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (iwCLL
             NCI-WG) criteria

          -  Subject has relapsed/refractory disease with an indication for treatment

          -  Subject has refractory disease or developed recurrence after therapy with a BCR PI

          -  Subject must have an Eastern Cooperative Oncology Group performance score of equal to
             or less than 2

          -  Subject must have adequate bone marrow function at Screening

          -  Subject must have adequate coagulation profile, renal, and hepatic function, per
             laboratory reference range at Screening

        Exclusion Criteria:

          -  Subject has undergone an allogeneic stem cell transplant within the past year

          -  Subject has developed Richter's transformation confirmed by biopsy

          -  Subject has active and uncontrolled autoimmune cytopenia

          -  Subject has malabsorption syndrome or other condition that precludes enteral route of
             administration

          -  Subject is human immunodeficiency virus (HIV) positive or has chronic hepatitis B or
             hepatitis C virus requiring treatment

          -  Subject has known contraindication or allergy to both xanthine oxidase inhibitors and
             rasburicase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalaja Potluri, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128535</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127262</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126495</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127261</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 131249</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126497</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126496</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134509</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 128536</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129648</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130011</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 127263</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126860</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 126498</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 130813</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncology</keyword>
  <keyword>Cancer of the blood and bone marrow</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Idelalisib</mesh_term>
    <mesh_term>Receptors, Antigen, B-Cell</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
